Nfocus CE marks brain aneurysm treatment
This article was originally published in Clinica
Nfocus Neuromedical has CE marked its flagship product, the Luna aneurysm embolisation system, for sale in Europe. It is designed to treat brain aneurysms both before and after rupture, which can lead to stroke, brain damage and death. Luna blocks blood flow to the aneurysm while providing a scaffold that encourages tissue growth across its opening, creating a plug. It is a self-expandable Nitinol implant that can be delivered via a conventional catheter and opened up to its full size once deployed within the aneurysm. Alternatives include surgery, which is "traumatic and expensive", and coils, which may fail to fully treat the aneurysm, according to Nfocus. The Palo Alto, California firm estimates that up to one in 15 people will develop a brain aneurysm in their lifetime.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.